U.S. Stock Night Market Movements
Neumora Therapeutics fell 3.27% in the night market. Based on recent key news:
<ol>
<li>
On June 16, Neumora Therapeutics' target price was lowered by HC Wainwright &amp; Co. from $18 to $7, leading to a significant drop in stock price. This move reflects market concerns about the company's future profitability, with the stock price falling approximately 44.86%. Source: Benzinga
</li>
<li>
On June 15, the company announced it would stop developing its depression drug navacaprant, as two late-stage trials failed to meet primary endpoints. This news caused the stock price to be halted in pre-market trading and triggered market panic. Source: Reuters
</li>
<li>
On June 16, Neumora Therapeutics released the Phase 3 results of its KOASTAL project, showing that navacaprant did not meet expectations, leading to a significant loss in shareholder value, with the stock price dropping approximately 50%. Source: Benzinga Pro The biopharmaceutical industry faces R&amp;D risks, with significant capital outflows.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Eli Lilly rose 0.13% in the night market. Based on recent key news:
<ol>
<li>
On June 16, Eli Lilly announced the acquisition of 4E Therapeutics, aiming to advance non-opioid treatment options for chronic pain. This move demonstrates Eli Lilly's strong interest in the pain relief market and its desire to find new growth engines beyond GLP-1 drugs, driving the stock price up.
</li>
<li>
On June 15, Barclays analyst Emily Field maintained a buy rating on Eli Lilly, setting a target price of $1,400. The analyst's positive rating boosted market confidence, supporting the rise in stock price.
</li>
<li>
On June 16, Eli Lilly plans to expand manufacturing and R&amp;D investments in the U.S. to address supply chain risks and tariff policies. This move helps enhance the company's competitiveness in the U.S. market, further driving the stock price up. The pharmaceutical industry is seeing active investment, with increasing market competition.
</li>
</ol>
Pfizer rose 0.12% in the night market. Based on recent key news:
<ol>
<li>
On June 15, Sinopharm Holdings and Pfizer officially established a strategic partnership, focusing on the promotion of the large-scale market and upgrading new product services. This move is expected to enhance Pfizer's influence in the Chinese market, driving the stock price up.
</li>
<li>
On June 16, Pfizer announced a dividend distribution of 0.37 Brazilian Reais per unit, with a payment date of June 18. This news may enhance investor confidence, supporting the rise in stock price.
</li>
<li>
On June 16, Pfizer reached licensing agreements with Arvinas and Rigel, obtaining Hart-Scott-Rodino approval, with Pfizer receiving a $70 million upfront payment from Rigel. This transaction may bring new revenue sources to Pfizer, boosting market sentiment. The pharmaceutical industry is expanding globally, with increased investment
Novo Nordisk's after-hours trading rose by 0.53%. Based on recent key news:
</li>
<li>
On June 17, senior executives from Novo Nordisk met with leaders from Tianjin to discuss laying out more high-quality products and innovative businesses in Tianjin, driving up the stock price. Jinshi Data reported this visit as a new starting point for cooperation, emphasizing a market-oriented business environment.
</li>
<li>
On June 15, Novo Nordisk announced an additional investment of 200 million RMB in its strategic production base in Tianjin to enhance the production capacity of the Chuangchong® injection pen, boosting market confidence. Viewpoint Network reported that this move will improve product capacity and supply efficiency.
</li>
<li>
On June 17, the FulcrumSec cyber ransom group claimed to have stolen over 1TB of data from Novo Nordisk and, after failing to obtain a ransom, is considering selling part of the data, increasing market uncertainty. Jinshi Data reported this incident. Industry innovation is accelerating, and the market environment is complex
</li>
</ol>

NMRA

Neumora Therapeutics fell 3.27% in after-hours trading; Eli Lilly rose 0.13% in after-hours trading, with a transaction volume of USD 606,200; Pfizer rose 0.12% in after-hours trading, with a transaction volume of USD 138,400; Novo Nordisk rose 0.53% in after-hours trading, with a transaction volume of USD 88,200

Price Alert

U.S. stock night market volatility: Neumora fell 3.27% in after-hours trading: core drug pipeline failure, target price halved